Loop Diuretics in Transfusion Management

Indications and Administration

The American College of Cardiology recommends administering furosemide when clinical signs of transfusion-associated circulatory overload (TACO) develop, including respiratory distress or increased oxygen requirements during/after transfusion, evidence of pulmonary edema on examination, and elevated jugular venous pressure or other signs of volume overload 1, 2, 3
In preterm neonates, the American Academy of Pediatrics suggests that transfusions are associated with increased oxygen requirement, which improves following furosemide administration, with a recommended dose based on clinical judgment 1, 2
The American Heart Association recommends that patients with acute heart failure and significant fluid overload should receive intravenous loop diuretics, with therapy beginning without delay as early intervention may improve outcomes, and the initial IV dose should equal or exceed their chronic oral daily dose 3

The American Academy of Pediatrics advises avoiding furosemide in neonatal hyperkalemia, as it can cause metabolic alkalosis that paradoxically worsens intracellular potassium shifts 4
The American College of Cardiology recommends not using furosemide in patients with hemodynamic instability or inadequate intravascular volume 3
The National Institute of Diabetes and Digestive and Kidney Diseases notes that furosemide can cause acute reductions in glomerular filtration rate, particularly with IV administration 5

The American Gastroenterological Association suggests that oral furosemide is preferred over IV in stable patients due to good bioavailability and risks of acute GFR reduction with IV administration 5
The American Heart Association recommends that for acute decompensated heart failure, IV administration is appropriate with doses equal to or exceeding chronic oral doses 3
The American Society of Hematology notes that slow transfusion rates (4-5 mL/kg/h) are more important than diuretics for preventing fluid overload, with even slower rates recommended for patients with reduced cardiac output 1, 2

The American College of Cardiology advises monitoring for diuretic-induced electrolyte disturbances (hypokalemia, hyponatremia) and renal function deterioration, particularly with repeated or high doses 3, 6
The National Institute of Child Health and Human Development recommends recognizing that furosemide has reduced clearance and prolonged half-life in neonates, making dosing unpredictable and increasing risks of ototoxicity and nephrocalcinosis 4

The American Society of Anesthesiologists recommends prophylactic furosemide for patients at high risk for transfusion-associated circulatory overload (TACO), particularly those with heart failure, renal failure, age >70 years, or low body weight, but should NOT be used routinely in all transfusion recipients 7, 8

Patients with age >70 years are at high risk for TACO, according to the American College of Cardiology 7, 8
Patients with heart failure, particularly with reduced ejection fraction, are at high risk for TACO, although the specific guideline society is not mentioned in this context 7, 8
Patients with renal failure, especially GFR <30 mL/min/1.73 m², are at high risk for TACO, as stated by the National Kidney Foundation 7, 8
Patients with hypoalbuminemia are at high risk for TACO, according to the American Heart Association 7, 8
Patients with low body weight are at high risk for TACO, as recommended by the American Society of Anesthesiologists 7, 8

The American Society of Anesthesiologists recommends monitoring respiratory rate throughout transfusion, as dyspnea and tachypnea are early TACO symptoms 7, 8
Body weight dosing of RBCs rather than standard unit dosing is recommended to prevent fluid overload, as suggested by the American Association of Blood Banks 7, 8
Close monitoring of vital signs and fluid balance throughout transfusion is necessary to prevent TACO, according to the American College of Cardiology 7, 8

The evidence base for prophylactic furosemide is weak, and it does NOT prevent acute kidney injury and may increase mortality when used inappropriately, as stated by the Kidney Disease: Improving Global Outcomes (KDIGO) foundation 9
Furosemide should ONLY be used for volume overload management, not for AKI prevention, as recommended by the National Kidney Foundation 9

The American College of Critical Care Medicine recommends beginning with 20 mg IV bolus or 3 mg/h infusion of furosemide for active TACO treatment, with the option to double each subsequent dose until goal achieved, and a maximum infusion rate of 24 mg/h and maximum bolus of 160 mg, not exceeding 620 mg/day 10
The Intensive Care Medicine journal suggests that furosemide should not be administered in patients with dialysis-dependent renal failure, oliguria with serum creatinine >3 mg/dL, or within 12 hours after last fluid bolus or vasopressor administration 10

The Society of Critical Care Medicine advises against administering furosemide in situations of hemodynamic instability, inadequate intravascular volume, neonatal hyperkalemia, dialysis-dependent renal failure, oliguria with serum creatinine >3 mg/dL, or within 12 hours after last fluid bolus or vasopressor administration 10

For patients with both impaired renal function and cardiac disease, the European Journal of Heart Failure recommends verifying systolic blood pressure ≥90-100 mmHg before furosemide administration, checking renal function, monitoring electrolytes, and assessing fluid status 11

In patients with significant renal dysfunction (creatinine >221 μmol/L [>2.5 mg/dL] or eGFR <30 mL/min/1.73 m²), specialist advice should be sought before administering furosemide, according to the European Journal of Heart Failure 11